Kenneth C. Cundy

Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs

Gary G. Liversidge, Kenneth C. Cundy · International Journal of Pharmaceutics · 1995 · 737 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue

William A. Lee, Gong-Xin He, Eugene Eisenberg et al. · Antimicrobial Agents and Chemotherapy · 2005 · 339 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071

Weixing Li, Paul A. Escarpe, Eugene Eisenberg et al. · Antimicrobial Agents and Chemotherapy · 1998 · 224 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

[54] In Vivo Oxidative DNA damage: Measurement of 8-Hydroxy-2′-deoxyguanosine in DNA and urine by high-performance liquid chromatography with electrochemical detection

Mark K. Shigenaga, Jeen‐Woo Park, Kenneth C. Cundy et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 1990 · 184 citations

Pharmacy, Biochemistry, Toxicology +16

Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( <i>R</i> )-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults

Steven G. Deeks, Patricia Barditch‐Crovo, Paul S. Lietman et al. · Antimicrobial Agents and Chemotherapy · 1998 · 158 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16